BTIG Research Issues Pessimistic Forecast for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price

Zevra Therapeutics (NASDAQ:ZVRA) had its price objective lowered by stock analysts at BTIG Research from $27.00 to $24.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s target price suggests a potential upside of 152.10% from the company’s current price.

Other equities analysts also recently issued reports about the company. Maxim Group lifted their target price on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Cantor Fitzgerald increased their price target on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday, June 9th. Guggenheim lifted their price objective on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $26.00 target price on shares of Zevra Therapeutics in a research note on Tuesday, June 23rd. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.86.

Zevra Therapeutics Price Performance

ZVRA opened at $9.52 on Monday. Zevra Therapeutics has a 52 week low of $7.16 and a 52 week high of $15.03. The business has a fifty day simple moving average of $12.37 and a 200-day simple moving average of $10.48. The firm has a market cap of $562.82 million, a P/E ratio of 4.78 and a beta of 0.85.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. The business had revenue of $36.22 million during the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. Sell-side analysts expect that Zevra Therapeutics will post 0.56 earnings per share for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Several large investors have recently bought and sold shares of the stock. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in Zevra Therapeutics during the 4th quarter worth about $53,000. Russell Investments Group Ltd. boosted its stake in shares of Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after buying an additional 4,475 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after buying an additional 8,552 shares in the last quarter. Creative Planning acquired a new position in shares of Zevra Therapeutics during the second quarter worth about $92,000. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Zevra Therapeutics during the second quarter worth approximately $99,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.